Advances in the Treatment of Myelofibrosis

A panel of experts discusses current strategies used to stratify risk in patients with myelofibrosis and their preferences for sequencing therapy.

EP. 1: Pathophysiology of Myelofibrosis

November 11th 2021

The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.

EP. 2: Symptom Assessments in Myelofibrosis

November 11th 2021

The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.

EP. 3: Risk Stratifying Patients With Myelofibrosis

November 15th 2021

Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.

EP. 4: Treatment Planning and Myelofibrosis

November 15th 2021

Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis

EP. 5: Stem Cell Transplants in Myelofibrosis

November 24th 2021

Best practices in determining eligibility and preparing patients with myelofibrosis for allogeneic stem cell transplantation.

EP. 6: Pharmacotherapy for Myelofibrosis

November 24th 2021

Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.

EP. 7: Approaching a Case of Primary Myelofibrosis

December 2nd 2021

Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis.

EP. 8: Assessing Treatment Response in Myelofibrosis

December 2nd 2021

Monitoring patient response to frontline therapy for myelofibrosis, and circumstances for which a change in therapy may be appropriate.

EP. 9: Second-Line Treatment Options for Myelofibrosis

December 6th 2021

Second-line therapies for myelofibrosis that are available or in the pipeline for use.

EP. 10: Second-Line Therapy for High-Risk Primary Myelofibrosis

December 6th 2021

Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.